Cardiac Rhythm Management Devices Market to See Robust Growth Through 2032, Fueled by Aging Demographics, AFib Burden, and Next-Gen Therapies | DelveInsight

The cardiac rhythm management (CRM) devices market is poised for steady expansion through 2032, driven by rising prevalence of atrial fibrillation and heart failure, an aging population, and broader adoption of minimally invasive and digitally connected cardiac care. Advancements in leadless pacemakers, subcutaneous ICDs, cardiac resynchronization therapy (CRT), and pulsed-field ablation (PFA) are improving procedural safety, battery longevity, and patient quality of life. Seamless remote monitoring, AI-enabled arrhythmia detection, and MRI-conditional systems are accelerating earlier intervention and long-term management. Growing penetration in emerging markets, supportive reimbursement for remote cardiac monitoring, and hospital focus on reducing readmissions further underpin demand-despite headwinds from pricing pressure, cybersecurity and data-integration needs, and supply chain variability.

DelveInsight's Cardiac Rhythm Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 report delivers granular current and forecast analysis, company market shares, therapy/technology trends (pacemakers, ICDs, CRT, ablation systems, diagnostics, and remote monitoring), key growth drivers and barriers, regulatory and reimbursement landscape, and profiles of leading and emerging players shaping the future of the CRM devices market.

Explore the latest trends and growth drivers in the cardiac rhythm management devices market-download your sample report now https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cardiac Rhythm Management Devices Market Report
• The global Cardiac Rhythm Management Devices market is projected to experience significant growth, expanding at a CAGR of 5.64%, and reaching a substantial value by 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global Cardiac Rhythm Management Devices market during the forecast period.
• Notable stereotactic surgery device companies such as Abbott, Medtronic, Boston Scientific Corporation, Koninklijke Philips N.V, Zoll Medical Corporation, Microport Scientific Corporation, LivaNova PLC, Stryker, Nihon Kohden Corporation, Biotronik, Inc., Shree Pacetronix Ltd., OSCOR Inc., Lepu Medical Technology Co. Ltd., BPL Medical Technologies, CU Medical Systems, Inc., SCHILLER AG, Bexen Cardio, Progetti S.r.l., Vitatron, Kestra Medical Technologies, Inc., and several others are currently operating in the Cardiac Rhythm Management Devices market.
• In April 2025, the FDA granted approval for EBR Systems' WiSE® System, the first-ever leadless left ventricular pacing device for cardiac resynchronization therapy (CRT).
• In April 2025, the FDA granted Breakthrough Device Designation to Orchestra BioMed's dual-chamber pacemaker algorithm-AVIM (atrioventricular interval modulation)-designed to treat uncontrolled hypertension.
• In February 2025, Johnson & Johnson paused U.S. sales of its Varipulse PFA system following reports of neurovascular events (including strokes) in several patients. The FDA is investigating while sales continue outside the U.S.
• In November 2024, Fourth Frontier announced that its Frontier X Plus ECG monitor received FDA 510(k) clearance. The wearable device wirelessly transmits real-time ECG data and uses advanced algorithms to classify cardiac rhythms, including Bradycardia, Tachycardia, and Atrial Fibrillation. It demonstrated excellent signal quality during exercise and showed equivalence to a 12-lead ECG in clinical trials conducted in the U.S. and India.

To read more about the latest highlights related to the cardiac rhythm management devices market, get a snapshot of the key highlights entailed in the global cardiac rhythm management devices market report here https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cardiac Rhythm Management Devices Overview
Cardiac rhythm management (CRM) devices are critical in diagnosing and treating heart rhythm disorders such as arrhythmias, bradycardia, and tachycardia. These devices include pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices, which help regulate and restore normal heart rhythms. Advances in CRM technology-such as leadless pacemakers, remote monitoring, and MRI-compatible systems-are improving patient outcomes and enhancing device functionality. With the rising global prevalence of cardiovascular diseases and an aging population, the demand for CRM devices continues to grow, making this a key segment in the cardiovascular medical devices market.

Cardiac Rhythm Management Devices Market Insights
North America is expected to dominate the cardiac rhythm management (CRM) devices market in 2023, driven by a high prevalence of heart rhythm disorders, rising risk factors such as smoking and diabetes, a well-established healthcare infrastructure, and the strong presence of key market players. According to the CDC (2022), around 20.1 million U.S. adults had coronary artery disease in 2020, and someone experiences a heart attack every 40 seconds. With 805,000 heart attacks occurring annually-many being recurrent or silent-the need for advanced CRM solutions is rising. Additionally, regulatory momentum, such as the FDA approval of Abbott's AveirTM leadless pacemaker in April 2022, is accelerating innovation and market growth. These factors collectively are expected to boost CRM device demand in North America from 2025 to 2032.

To know more about why North America is leading the market growth in the cardiac rhythm management devices market, get a snapshot of the cardiac rhythm management devices market outlook here https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cardiac Rhythm Management Devices Market Dynamics
The global cardiac rhythm management devices market is expected to grow significantly, driven by the rising burden of cardiovascular diseases and associated risk factors. According to the American Heart Association (2022), approximately 244.1 million people worldwide were living with coronary heart disease in 2020, with the highest prevalence in regions like North Africa, the Middle East, and Central and South Asia. Similarly, the British Heart Foundation (2022) reported that around 550 million people globally were affected by heart and circulatory diseases in 2019, including 290 million women and 260 million men. Common cardiovascular conditions such as coronary artery disease, peripheral arterial disease, stroke, and atrial fibrillation remain highly prevalent.

Risk factors like obesity, hypertension, diabetes, smoking, aging, and sedentary lifestyles continue to fuel disease incidence. According to WHO (2022), the global population over age 60 reached 1 billion in 2020 and is projected to more than double by 2050. Additionally, the International Diabetes Federation (2021) reported that 537 million adults globally were living with diabetes, further exacerbating cardiac risk. Despite these drivers, the complex nature of cardiac rhythm disorders and stringent regulatory pathways may pose challenges to market growth.

Get a sneak peek at the cardiac rhythm management devices market dynamics @ https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coverage: Global
Study Period: 2022 to 2032
Cardiac Rhythm Management Devices Market CAGR: ~5.64%
Key Cardiac Rhythm Management Devices Companies: Abbott, Medtronic, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, Microport Scientific Corporation, LivaNova PLC, Stryker, Nihon Kohden Corporation, Biotronik, Inc., Shree Pacetronix Ltd., OSCOR Inc., Lepu Medical Technology Co. Ltd., BPL Medical Technologies, CU Medical Systems, Inc., SCHILLER AG, Bexen Cardio, Progetti S.r.l., Vitatron, Kestra Medical Technologies, Inc., and others.

Cardiac Rhythm Management Devices Market Segmentation
Market Segmentation By Product Type: Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) Devices.
Market Segmentation By End User: Hospitals, Cardiac Centers, and others.
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the cardiac rhythm management devices market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Cardiac Rhythm Management Devices Market Report Introduction
2. Cardiac Rhythm Management Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Cardiac Rhythm Management Devices Market Key Factors Analysis
6. Cardiac Rhythm Management Devices Market Porter's Five Forces Analysis
7. Cardiac Rhythm Management Devices Market Layout
8. Cardiac Rhythm Management Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Us
Jatin Vimal
jvimal@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.